Mark Lamotte

Validation of the IMS CORE Diabetes Model

Phil McEwan, V. Foos, James L. Palmer et al. · Value in Health · 2014 · 229 citations

Incidence, Medical Resource Utilisation and Costs of Hyperuricemia and Tumour Lysis Syndrome in Patients with Acute Leukaemia and Non-Hodgkin's Lymphoma in Four European Countries

L Annemans, K Moeremans, Mark Lamotte et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2002 · 151 citations

Renal Pathology, Pathology, Tls Cases +17

Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive Medications Excluding ACE Inhibitors, Other Angiotensin-2 Receptor Antagonists, and Dihydropyridine Calcium Channel Blockers) or Late Irbesartan Treatment in Patients With Type 2 Diabetes, Hypertension, and Renal Disease

Andrew Palmer, Lieven Annemans, Stéphane Roze et al. · Diabetes Care · 2004 · 93 citations · Full text

Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Europe

Kornelia Kotseva, Laetitia Gerlier, Eduard Sidelnikov et al. · European Journal of Preventive Cardiology · 2019 · 91 citations

Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients

Lieven Annemans, K Moeremans, Mark Lamotte et al. · Supportive Care in Cancer · 2003 · 77 citations

Tumour Lysis Syndrome, Urology, Oncology +7